Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murat Kurt

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Pharmacoeconomics - Open|August 25, 2022
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067Timothy Baker, Helen Johnson, Srividya Kotapati, et al.
European Journal of Cancer (Oxford, England : 1990)|May 23, 2022
Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysisJaffer A Ajani, Lisa Leung, Prianka Singh, et al.
Journal of Pediatric Orthopedics. Part B|November 11, 2005
Alternative reliable techniques in femoral torsion measurementM Onder Delialioglu, Bulent A Tasbas, Kenan Bayrakci, et al.
Pharmacoeconomics|January 11, 2021
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell CarcinomaSven L Klijn, Elisabeth Fenwick, Sonja Kroep, et al.
Case Reports in Neurological Medicine|January 24, 2014
Syncope associated with subthalamic nucleus deep brain stimulation in a patient with Parkinson's diseaseDursun Aygun, Ersoy Kocabicak, Onur Yildiz, et al.
Frontiers in Oncology|June 20, 2025
Predicting overall survival benefit in previously untreated, unresectable or metastatic melanoma from improvement in progression-free survival: a correlation meta-analysisPeter Mohr, Murat Kurt, Swetha Srinivasan, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 3, 2011
Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherenceJennifer E Mason, Darin A England, Brian T Denton, et al.
Journal of Medical Economics|February 22, 2024
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placeboSiguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, et al.
Plos One|February 2, 2011
Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patientsNilay D Shah, Jennifer Mason, Murat Kurt, et al.
Clinical Genitourinary Cancer|April 9, 2025
Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 TrialDaniel M Geynisman, Kateryna Chepynoga, Georgia Yates, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Pharmacoeconomics - Open|August 25, 2022
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067Timothy Baker, Helen Johnson, Srividya Kotapati, et al.
European Journal of Cancer (Oxford, England : 1990)|May 23, 2022
Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysisJaffer A Ajani, Lisa Leung, Prianka Singh, et al.
Journal of Pediatric Orthopedics. Part B|November 11, 2005
Alternative reliable techniques in femoral torsion measurementM Onder Delialioglu, Bulent A Tasbas, Kenan Bayrakci, et al.
Pharmacoeconomics|January 11, 2021
What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell CarcinomaSven L Klijn, Elisabeth Fenwick, Sonja Kroep, et al.
Case Reports in Neurological Medicine|January 24, 2014
Syncope associated with subthalamic nucleus deep brain stimulation in a patient with Parkinson's diseaseDursun Aygun, Ersoy Kocabicak, Onur Yildiz, et al.
Frontiers in Oncology|June 20, 2025
Predicting overall survival benefit in previously untreated, unresectable or metastatic melanoma from improvement in progression-free survival: a correlation meta-analysisPeter Mohr, Murat Kurt, Swetha Srinivasan, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 3, 2011
Optimizing statin treatment decisions for diabetes patients in the presence of uncertain future adherenceJennifer E Mason, Darin A England, Brian T Denton, et al.
Journal of Medical Economics|February 22, 2024
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placeboSiguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, et al.
Plos One|February 2, 2011
Comparative effectiveness of guidelines for the management of hyperlipidemia and hypertension for type 2 diabetes patientsNilay D Shah, Jennifer Mason, Murat Kurt, et al.
Clinical Genitourinary Cancer|April 9, 2025
Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 TrialDaniel M Geynisman, Kateryna Chepynoga, Georgia Yates, et al.
Pageof 5